CA3059000C - Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto - Google Patents

Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto

Info

Publication number
CA3059000C
CA3059000C CA3059000A CA3059000A CA3059000C CA 3059000 C CA3059000 C CA 3059000C CA 3059000 A CA3059000 A CA 3059000A CA 3059000 A CA3059000 A CA 3059000A CA 3059000 C CA3059000 C CA 3059000C
Authority
CA
Canada
Prior art keywords
disease
prop
pyrrolo
methylpiperidin
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3059000A
Other languages
English (en)
French (fr)
Other versions
CA3059000A1 (en
Inventor
Douglas James Critcher
David Sydney Bernard Daniels
Brian Matthew Samas
Yong Tao
Kevin Paul Girard
Gregory Scott Goeken
Peter Robert Rose
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA3059000A1 publication Critical patent/CA3059000A1/en
Application granted granted Critical
Publication of CA3059000C publication Critical patent/CA3059000C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3059000A 2018-10-22 2019-10-17 Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto Active CA3059000C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862748628P 2018-10-22 2018-10-22
US62/748628 2018-10-22

Publications (2)

Publication Number Publication Date
CA3059000A1 CA3059000A1 (en) 2020-04-22
CA3059000C true CA3059000C (en) 2026-04-14

Family

ID=68343187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3059000A Active CA3059000C (en) 2018-10-22 2019-10-17 Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto

Country Status (15)

Country Link
US (1) US12116368B2 (https=)
EP (1) EP3870584A1 (https=)
JP (1) JP6944496B2 (https=)
KR (1) KR102629132B1 (https=)
CN (1) CN112888691B (https=)
AR (1) AR116797A1 (https=)
AU (1) AU2019363840B2 (https=)
BR (1) BR112021007568A2 (https=)
CA (1) CA3059000C (https=)
IL (1) IL282446B2 (https=)
MX (1) MX2021003241A (https=)
SG (1) SG11202103667QA (https=)
TW (1) TWI729530B (https=)
WO (1) WO2020084435A1 (https=)
ZA (1) ZA202101735B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020338043B2 (en) 2019-08-26 2025-12-18 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
KR20220123271A (ko) * 2019-12-31 2022-09-06 화이자 알앤디 유케이 리미티드 1-((2S,5R)-5-((7H-피롤로[2,3-d]피리미딘-4-일)아미노)-2-메틸피페리딘-1-일)프로프-2-엔-1-온의 안정한 즉시 방출형 정제 및 캡슐 제형
CN113121539A (zh) * 2019-12-31 2021-07-16 江苏艾立康医药科技有限公司 一种pf06651600的制备方法
CN111732591B (zh) * 2020-06-15 2022-06-10 江苏艾立康医药科技有限公司 Pf-06651600 l-酒石酸盐，晶型及其制备方法
CN111620880B (zh) * 2020-06-15 2022-06-10 江苏艾立康医药科技有限公司 Pf-06651600 dl-酒石酸盐，晶型及其制备方法
CN114835715B (zh) * 2020-06-15 2024-04-05 江苏艾立康医药科技有限公司 Pf-06651600马来酸盐及其制备方法
WO2022012587A1 (zh) * 2020-07-14 2022-01-20 苏州晶云药物科技股份有限公司 丙烯酮类化合物的丙二酸盐晶型及其制备方法
KR102473645B1 (ko) * 2020-08-28 2022-12-05 (주)부흥산업사 (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN112877379B (zh) * 2021-01-18 2023-09-01 华南理工大学 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法
WO2025144783A1 (en) * 2023-12-28 2025-07-03 Aclaris Therapeutics, Inc. Methods of synthesizing substituted pyrrolopyrimidine compounds
WO2025146702A1 (en) * 2024-01-03 2025-07-10 Msn Laboratories Private Limited, R&D Center Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid
WO2025219875A1 (en) * 2024-04-17 2025-10-23 Alembic Pharmaceuticals Limited Solid forms of ritlecitinib or its salts
CN118420493B (zh) * 2024-04-24 2026-04-14 山东福长药业有限公司 一种2,5-二取代氨基己酸酯的制备方法及使用其制备利特昔替尼的方法
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent
WO2025257773A1 (en) 2024-06-11 2025-12-18 Assia Chemical Industries Ltd. Processes for the preparation of ritlecitinib and intermediates thereof
CN119060059B (zh) * 2024-08-21 2025-10-28 武汉九州钰民医药科技有限公司 一种甲苯磺酸利特昔替尼的制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
MX368464B (es) * 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN105859721B (zh) * 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法

Also Published As

Publication number Publication date
CA3059000A1 (en) 2020-04-22
US20210387989A1 (en) 2021-12-16
SG11202103667QA (en) 2021-05-28
TWI729530B (zh) 2021-06-01
EP3870584A1 (en) 2021-09-01
AR116797A1 (es) 2021-06-16
AU2019363840A1 (en) 2021-04-01
ZA202101735B (en) 2022-07-27
JP6944496B2 (ja) 2021-10-06
KR20210080468A (ko) 2021-06-30
US12116368B2 (en) 2024-10-15
BR112021007568A2 (pt) 2021-07-27
KR102629132B1 (ko) 2024-01-29
TW202033525A (zh) 2020-09-16
CN112888691A (zh) 2021-06-01
MX2021003241A (es) 2021-05-12
IL282446B1 (en) 2024-02-01
JP2020066629A (ja) 2020-04-30
WO2020084435A1 (en) 2020-04-30
IL282446B2 (en) 2024-06-01
IL282446A (en) 2021-06-30
AU2019363840B2 (en) 2021-12-09
CN112888691B (zh) 2023-10-31

Similar Documents

Publication Publication Date Title
CA3059000C (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
JP6530792B2 (ja) Ｓｙｋ阻害剤
CA3167093A1 (en) Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
TWI820301B (zh) 結晶型嘧啶基－３，８－二氮雜雙環〔３．２．１〕辛烷基甲酮化合物及其用途
JP2020502224A (ja) ヤヌスキナーゼ阻害剤の結晶形
US20250026760A1 (en) Solid forms of jak inhibitor and process of preparing the same
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
RU2849555C2 (ru) Тозилат пирроло[2,3-d]пиримидина, его кристаллическая форма и способ получения и промежуточные продукты для этой цели
HK40054619B (zh) 吡咯并[2，3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体
HK40054619A (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
HK1256999B (en) Syk inhibitors
HK1230609B (en) Syk inhibitors
HK1230609A1 (en) Syk inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220526

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250828

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250915

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250915

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251118

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260227

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20260408

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20260414